Phase II study of imatinib mesylate in patients with life threatening malignant rare diseases.

Trial Profile

Phase II study of imatinib mesylate in patients with life threatening malignant rare diseases.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2012

At a glance

  • Drugs Imatinib (Primary)
  • Indications Cancer; Dermatofibrosarcoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 19 Apr 2012 Actual end date (1 Jan 2007) added as reported by ClinicalTrials.gov.
    • 07 Sep 2007 Status changed from in progress to completed
    • 11 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top